Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Elucidating and targeting the mechanisms encoded in the genome of long-lived individuals to improve healthy ageing

Project description

Genetic factors that determine health in old age

According to the World Health Organization, 1 in 6 people in the world will be aged 60 years or over by 2030. While living longer is certainly desirable, ageing has been linked to many challenges such as serious illnesses. However, there are some individuals who age well and seem to escape or delay age-related diseases. The EU-funded ElucidAge project seeks to shed light on this phenomenon by investigating genetic variants that are unique to long-lived individuals. The project will use cell culture and animal models such as mice to examine if and how the genes containing these variants play an active role in health in advanced age.

Objective

Advancing age is the major risk factor for many serious illnesses, including cancer, cardiovascular disease, and dementia. The rising number of older individuals is thus causing a major burden of ill health. However, individuals that reach an exceptional old age often seem to escape or delay age-related diseases, and part of this trait seems to be encoded in their genome. Hence, by studying the genome of long-lived individuals, we may be able to identify mechanisms that could be targeted for healthy ageing in the general population. My previous work suggests that large genome-wide association studies (GWAS) of long-lived individuals can be used to identify genetic variants involved in longevity. However, the common genetic variants thus far identified using GWAS only explain a minor part of the genetic component of longevity. This trait, therefore, may well be mainly determined by rare genetic variants, which can be detected using whole-genome or exome sequencing of long-lived families or exceptionally long-lived individuals. The aim of the proposed project is to establish the effect of genetic variants identified in genetic studies of long-lived individuals on general health and lifespan using cellular models and, subsequently, model organisms. To this end, I will use CRISPR/Cas9 gene editing to generate transgenic cell lines and mice that harbour genetic variants in candidate genes and pathways identified through GWAS and sequencing studies of long-lived families and individuals. I will subsequently use this information to create a high-throughput screening assay to identify compounds that can pharmacologically recapitulate the observed in vitro effects. As a proof-of-principle, I will start with functional characterisation of rare variants in genes involved in insulin/insulin-like growth factor 1 (IIS) and mammalian target of rapamycin (mTOR) signalling, given the well-known role of these networks in ageing in pre-clinical model organisms.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2021-STG

See all projects funded under this call

Host institution

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 121 875,00
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 121 875,00

Beneficiaries (2)